Total n=44 | No pyrexia n=28 | Pyrexia n=16 | |||
---|---|---|---|---|---|
Sex | |||||
Male | 21 | 15 | 6 | ||
Female | 23 | 13 | 10 | ||
Mean Age in years, (SD) | 71.9 (11.4) | 71.9 (11.7) | 71.9 (11.3) | p=0.990 | |
Stroke Subtype | |||||
TACS | 14 | 5 | 9 | TACS vs | |
PACS | 19 | 14 | 5 | non-TACS | |
LACS | 6 | 6 | 0 | χ2=6.9 | |
POCS | 5 | 3 | 2 | p=0.009 | |
Stroke severity | |||||
Median NIHSS (IQR) | 7 (3–14) | 6.5 (3–10) | 12 (5–18) | p=0.0381 (MWU) | |
Temperature | |||||
Time to peak, median hours after stroke, (IQR) | 35.5 (19–53.8) | 36.0 (7.8-59.3) | 32.5 (22.8-51.3) | p=0.652 (MWU) | |
N o . with ≥1 pyrogenic factor identified* | 16 (36%) | 7 (25%) | 9 (56%) | ||
Urinary catheter | 8 | 3 | 5 | ||
NG tube | 9 | 4 | 5 | ||
Surgical procedure | 4 | 2 | 2 | ||
DVT | 0 | 0 | 0 | ||
Infection: urinary | 2 | 0 | 2 | ||
Infection: respiratory | 7 | 4 | 3 | ||
Antibiotics | 10 | 4 (14%) | 6 (38%) | ||
Paracetamol | 13 | 7 (25%) | 6 (38%) | ||
Thrombolysis | 3 | 1 (4%) | 2 (13%) | ||
90 day mRS | |||||
mRS ≤2 | 19 | 15 | 4 | χ2=3.5 | |
mRS ≥3 | 25 | 13 | 12 | p=0.061 |